VI.7 Vaccine recommendations for patients on chronic HD (except HB vaccination)

Guideline VI.7.1

A. Pneumococcal polysaccharide vaccine may be recommended especially in the elderly HD patients.
Revaccination is also recommended 5 years after the previous dose.

(Evidence level: C)

Commentary on Guideline VI.7.1

More than 75% of the dialysis patients have an adequate response to the vaccine [219–222] but their antibody titres are considerably less than those of healthy vaccinated adults [219,220,223] and decline rapidly [219–221].

The Advisory Committee on Immunization Practice (ACIP) recommended a standard vaccination to all dialysis patients 2 years of age or older and revaccination 3–5 years after the first dose of pneumococcal vaccine [224].

Guideline VI.7.2

A. Influenza vaccine is recommended annually before the beginning of the influenza season for HD patients.

(Evidence level: B)

Commentary on Guideline VI.7.2

In HD patients there is an increased risk of influenza-related mortality [225,226]. Influenza vaccination of HD patients according to current recommendations results in an effective humoral immune response [227,228] but the post-vaccination titre is often less in dialysis patients than in immunocompetent subjects [227–229].

Guideline VI.7.3

A. Patient on dialysis should receive the diphtheria and tetanus toxoids as recommended for healthy people.

(Evidence level: B)

Commentary on Guideline VI.7.3

All inactivated vaccines and toxoids are safe and effective when used in dialysis patients. These patients should receive the same doses and schedules recommended for immunocompetent persons [230,231]. In adults the standard anti-tetanus vaccination produces satisfactory response but a rapid decline in antibody titres sometimes occurs leading to an absence of protection 6 months later [232].

References


SECTION VI. Haemodialysis-associated infection

2. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58: 1758–1764 (B)


SECTION VI. Haemodialysis-associated infection


27. Bloembergen WE, Port FK. Epidemiological perspective on infections in chronic dialysis patients. Adv Ren Replace Ther 1996; 3: 34–37 (B)


32. Bloembergen WE, Port FK. Epidemiological perspective on infections in chronic dialysis patients. Adv Ren Replace Ther 1996; 3: 34–37 (B)


40. Goldblum SE, Reed WP. Host defenses and immunologic alterations associated with chronic hemodialysis. Am Intern Med 1994; 130: 653–663 (C)


42. Haag-Weber M, Horl WH. Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uremia? Nephrol Dial Transplant 1996; 11 [Suppl 2]; 98–100 (C)


54. NKF DOQI Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 35 [Suppl 2]; S20–S21 (C)


58. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458–482 (B)


60. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993; 44: 115–119 (B)


64. European Best Practice Guidelines for the management of patients with chronic renal failure. Target haemoglobin concentration for the treatment of anaemia of chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 15]; 11–13 (C)

84 SECTION VI. Haemodialysis-associated infection


78. Collart FE, Dratwa M, Wittek M, Wens R. Effects of recombinant human erythropoietin on T lymphocyte subsets in haemodialysis patients. ASAO Trans 1990; 36: M219–M223 (B)


84. Boelaert JR, Van Landuyt HW, Valcke YJ et al. The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremia in hemodialysis patients. J Infect Dis 1987; 156: 384–387 (B)

85. Boelaert JR, Van Landuyt HW, Valcke YJ et al. The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremias in hemodialysis patients. J Infect Dis 1987; 156: 384–387 (B)

86. Tielemans C, Lenclud C. Respective role of haemosiderosis and desferoxamine therapy in the risk in infection from haemodialysed patients. Q J Med 1988; 68: 573–574 (B)


96. Koda Y, Seo K et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096–1101 (B)


125. Anderson JE, Chang ASY, Anstadt MP. Polytetrafluoroethylene graft survival in hemodialysis. Surgery 1980; 87: 445–450 (B)


127. Bhat DJ, Tellis VA, Kohlberg WI, Driscoll B, Veth FJ. Management of sepsis involving expanded polytetrafluoroethylene grafts for hemodialysis access. Surgery 1980; 87: 445–450 (B)


137. Smirnoff M, Patt C, Seckler B, Adler JJ. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998; 113: 25–27 (B)


153. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969; 50: 81–114 (B)

154. Controlled trial of 2, 4, and 6 months of pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969; 50: 81–114 (B)

155. Van der Poel CL, Cuypers HT, Reesink HW et al. Controlled trial of 2, 4, and 6 months of pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969; 50: 81–114 (B)

156. Pereira BJ, Levey AS, Hepatitis C virus infection in dialysis units. Nephron 1995; 70: 301–306 (B)

157. Van der Poel CL, Cuypers HT, Reesink HW et al. Controlled trial of 2, 4, and 6 months of pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969; 50: 81–114 (B)


159. Natov SN, Pereira BJ. Routine serologic testing for hepatitis C virus infection should be instituted among dialysis patients. Semin Dial 2000; 13: 393–398 (C)


SECTION VI. Haemodialysis-associated infection


169. Sampietro M, Badalamenti S, Salvadori S et al. Molecular evidence for nosocomial spread of two different hepatitis C virus strains in one hemodialysis unit. *Nephron* 1997; 77: 273–278 (B)


172. Favero MS. Recommended precautions for patients undergoing hemodialysis who have AHE, BHE or non-A, non-B hepatitis. *Infect Control Hosp Epidemiol* 1985; 6: 301–305 (C)


206. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in haemodialysis patients.


211. Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. *J Infect Dis* 1983; 148: 335 (B)


